High-flux acetate haemodialysis: a single-centre experience.
One hundred haemodialysed patients have been treated for 4 h thrice weekly by acetate haemodialysis with high-flux dialysers (HAHD) 1.4-1.8 m2 and automated ultrafiltration control for 18.9 +/- 8.3 months. The aim of the study was to evaluate the efficacy of treatment as regards urea and beta 2-microglobulin removal, cardiovascular stability, acid-base balance and plasma Il-1 variations. Moreover medium-term observation of both lipid profile and basal beta 2-microglobulin concentrations were performed. With our current adequacy criteria (urea clearance greater than or equal to 120 l/week; KT/V greater than or equal to 1.2; beta 2-microglobulin removal greater than or equal to 150 mg/treatment), the occurrence of hypotension was 6% during 24,500 treatments. Cardiovascular stability was preserved by the increase of total peripheral resistances in response to cardiac output decrease. No disturbances of acid-base parameters were observed in spite of plasma acetate concentrations greater than 6 mmol/l. No variations of plasma Il-1 occurred during the session or 2 h later.
Civati
G
G
Divisione Nefrologia e Dialisi, Ospedale Niguarda Cà-Granda, Milano, Italy.
Guastoni
C
C
Teatini
U
U
Perego
A
A
Perrino
M L
ML
Benazzi
E
E
Minetti
L
L
D000085:Acetates / Q000627:therapeutic use*; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007022:Hypotension / Q000209:etiology; D007375:Interleukin-1 / Q000097:blood; D007444:Inulin / Q000378:metabolism; D007676:Kidney Failure, Chronic / Q000097:blood / Q000503:physiopathology / Q000628:therapy; D006435:Renal Dialysis / Q000379:methods*; D014280:Triglycerides / Q000097:blood; D001613:beta 2-Microglobulin / Q000378:metabolism
D000085:Acetates; D008076:Cholesterol, HDL; D007375:Interleukin-1; D014280:Triglycerides; D001613:beta 2-Microglobulin; D007444:Inulin; D002784:Cholesterol